RELEASE DETAILS

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 29, 2019-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will participate in the following upcoming conferences in September:

2019 Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2019
Fireside Chat Time: 8:00 a.m.
Location: Boston, MA

H.C. Wainwright 21^st Annual Global Investment Conference
Date: Tuesday, September 10, 2019
Presentation Time: 10:50 a.m.
Location: New York, NY

To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018FDA approval of INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005004/en/

Source: Kala Pharmaceuticals, Inc.

Investors:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

or

Media:
Kari Watson
kwatson@macbiocom.com
781-235-3060